News | July 21, 2014

Texas' First Accredited Pediatric Heart Failure Institute Is Texas Children's Hospital

July 21, 2014 – The Healthcare Accreditation Colloquium announced that Texas Children's Hospital has earned the designation of Accredited Pediatric Heart Failure Institute following 12 months of work and an extensive onsite review. 
 
"The approach to heart failure at Texas Children's Hospital is one of the broadest ranging comprehensive programs in the U.S.," said Dr. Frank Smart, Colloquium Board Chair. "They care for the sickest children daily, yet remain committed to breakthrough research that has the potential to change medicine for everyone." 
 
The heart failure leadership team at Texas Children's Hospital worked in four domains to achieve heart failure accreditation: The Community, Hospital, Clinician, and Science. In the community their preventative screening program for sudden cardiac arrest in young people was especially notable. The hospital itself is an integrated small city where pediatric patients can actually go to an accredited classroom for their schooling while on ventricular assist devices and after heart transplantation. In the Clinician Domain, physician and nurse education is part of the institutional culture. Novel approaches to practical applications of science are everywhere. One example is the "Just in Time" scenario room where world-class clinicians can come together and practice possible clinical scenarios to prepare themselves anticipating emergencies before they take place.
 
"The Colloquium is about bringing together experts to improve heart failure care for children across the entire continuum of care," said Dr. Daniel J. Penny, chief of cardiology at Texas Children's Hospital. "We are delighted that Texas Children's is a recognized member of this expert group. We look forward to working with The Colloquium wherever children with heart failure have a need." 
 
The Colloquium is the first organization to develop an improvement science based approach to pediatric heart failure accreditation. Member hospitals conduct the site visits following the guidelines developed by all member hospitals, making the Colloquium's approach to accreditation unique in America. The site reviewers were Frank W. Smart, MD, FACC, (Colloquium Board Chair) and Sonja H. Dahl, DNP, RN, CPNP, (Heart Failure Leadership Team Coordinator at Mayo Clinic in Rochester, Minnesota). 
 
For more information, visit: http://colloquiumhealth.com/

Related Content

Novel Therapeutic Approach Effective at Reducing Pressure for Heart Failure Patients

Image courtesy of Kapur N.K., Karas R.H., Burkhoff D., et al.

News | Heart Failure | June 17, 2019
Results from a first-in-man proof of concept study found occlusion of the superior vena cava (SVC) rapidly and...
Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis (Vyndamax) capsules for the treatment of the cardiomyopathy.

Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. 

Technology | Heart Failure | May 06, 2019
May 6, 2019 — The U.S.
The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

Feature | Heart Failure | April 29, 2019 | Will Clifton, M.D.
The heart and kidneys are inextricably linked through a diverse web of hemodynamic, neural and hormonal mechanisms.
Diabetes Drug May Reverse Heart Failure
News | Heart Failure | April 19, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic...
Diabetes Drug Effective Against Heart Failure in Wide Spectrum of Patients
News | Heart Failure | March 29, 2019
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are...
New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.
News | Heart Failure | March 27, 2019
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsa
Toilet Seat Detects Congestive Heart Failure

Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, is part of the university team that has developed a toilet-seat based cardiovascular monitoring system. Image courtesy of A. Sue Weisler/RIT.

News | Heart Failure | March 26, 2019
March 26, 2019 — A toilet seat-based ...
FDA Approves Optimizer Smart System for Heart Failure Patients offers cardiac contractility modulation.
Technology | Heart Failure | March 21, 2019
The U.S. Food and Drug Administration (FDA) approved Impulse Dynamics’ Optimizer Smart system for treating patients...
William T. Abraham, M.D., Joins V-Wave as Chief Medical Officer

William T. Abraham, M.D., in an interview with DAIC Editor Dave Fornell at TCT 2016.

News | Heart Failure | March 12, 2019
V-Wave Ltd. announced that renowned heart failure cardiologist William T. Abraham, M.D., is joining V-Wave as chief...
Overlay Init